Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:33:51 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



Q:AXGN - AXOGEN INC - http://www.axogeninc.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AXGN - Q0.15.75·6.330.15.79-0.09-1.5307.11,6512,1285.89  6.18  5.7110.8324  3.45May 03May 0215 min RT 2¢

Recent Trades - Last 10 of 2128
Time ETExPriceChangeVolume
16:10:36Q5.74-0.14250
16:00:07Q5.785-0.09528
16:00:06Q5.785-0.09531
16:00:02Q5.785-0.095123
16:00:01Q5.79-0.091,570
16:00:01Q5.79-0.09355
16:00:01Q5.79-0.091,329
16:00:01Q5.79-0.09173
16:00:01Q5.79-0.09366
16:00:01Q5.79-0.092,798

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-02 07:00U:AXGNNews ReleaseAxogen, Inc Reports First Quarter 2024 Financial Results
2024-04-29 16:50U:AXGNNews ReleaseAxogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix(TM)
2024-04-16 07:00U:AXGNNews ReleaseAxogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
2024-03-05 07:00U:AXGNNews ReleaseAxogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
2024-02-13 16:30U:AXGNNews ReleaseAxogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
2024-02-02 16:15U:AXGNNews ReleaseCompany Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2024-01-18 17:00U:AXGNNews ReleaseAxogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
2024-01-04 16:45U:AXGNNews ReleaseAxogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
2024-01-04 16:40U:AXGNNews ReleaseAxogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
2024-01-04 16:35U:AXGNNews ReleaseAxogen Announces Promotions on Research and Development Team
2023-12-26 16:15U:AXGNNews ReleaseAxogen, Inc. Appoints Kathy Weiler to its Board of Directors
2023-12-06 07:00U:AXGNNews ReleaseAxogen Announces Transition of Finance Team Leadership
2023-12-01 17:00U:AXGNNews ReleaseCompany Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-20 07:00U:AXGNNews ReleaseAxogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference
2023-11-07 07:00U:AXGNNews ReleaseAxogen, Inc. Reports 2023 Third Quarter Financial Results
2023-10-18 07:00U:AXGNNews ReleaseAxogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023
2023-09-05 07:00U:AXGNNews ReleaseAxogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector ¢ „ ¢
2023-08-31 07:00U:AXGNNews ReleaseAxogen to Participate at Upcoming Investor Conferences
2023-08-21 07:00U:AXGNNews ReleaseAxogen, Inc. Begins Processing Avance ‚ ® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio
2023-08-07 16:01U:AXGNNews ReleaseAxogen, Inc. Reports 2023 Second Quarter Financial Results